Monopar Therapeutics Inc. (NASDAQ:MNPR) Short Interest Update

Monopar Therapeutics Inc. (NASDAQ:MNPR - Get Free Report) saw a significant decline in short interest during the month of May. As of May 15th, there was short interest totalling 38,000 shares, a decline of 13.8% from the April 30th total of 44,100 shares. Currently, 1.0% of the company's shares are short sold. Based on an average daily trading volume, of 25,800 shares, the short-interest ratio is presently 1.5 days.

Insiders Place Their Bets

In other Monopar Therapeutics news, major shareholder Tactic Pharma Llc sold 33,334 shares of Monopar Therapeutics stock in a transaction on Wednesday, April 2nd. The stock was sold at an average price of $35.00, for a total value of $1,166,690.00. Following the sale, the insider now owns 822,255 shares in the company, valued at $28,778,925. The trade was a 3.90% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 20.50% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the business. AlphaQuest LLC acquired a new position in shares of Monopar Therapeutics during the 1st quarter worth about $44,000. JPMorgan Chase & Co. acquired a new position in shares of Monopar Therapeutics during the 4th quarter worth about $45,000. Gerber LLC acquired a new position in shares of Monopar Therapeutics during the 1st quarter worth about $204,000. OMERS ADMINISTRATION Corp acquired a new position in shares of Monopar Therapeutics during the 1st quarter worth about $328,000. Finally, Jane Street Group LLC acquired a new position in shares of Monopar Therapeutics during the 1st quarter worth about $377,000. 1.83% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on MNPR. Jones Trading reiterated a "hold" rating on shares of Monopar Therapeutics in a report on Wednesday, April 2nd. Wall Street Zen upgraded Monopar Therapeutics from a "sell" rating to a "hold" rating in a report on Thursday, May 22nd. Piper Sandler reiterated an "overweight" rating and issued a $76.00 price objective on shares of Monopar Therapeutics in a report on Wednesday, March 19th. Finally, HC Wainwright reiterated a "buy" rating and issued a $40.00 price objective on shares of Monopar Therapeutics in a report on Tuesday, April 1st. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to data from MarketBeat.com, Monopar Therapeutics presently has a consensus rating of "Moderate Buy" and an average target price of $55.33.

Monopar Therapeutics Stock Down 2.4%

NASDAQ MNPR traded down $0.90 during trading hours on Friday, hitting $37.11. 19,857 shares of the company were exchanged, compared to its average volume of 359,982. The company has a 50 day moving average of $36.97 and a two-hundred day moving average of $33.68. Monopar Therapeutics has a 52-week low of $1.72 and a 52-week high of $54.30. The firm has a market cap of $226.93 million, a price-to-earnings ratio of -18.84 and a beta of 0.99.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) last issued its quarterly earnings results on Tuesday, May 13th. The company reported ($0.38) earnings per share for the quarter, topping the consensus estimate of ($0.65) by $0.27. On average, equities research analysts predict that Monopar Therapeutics will post -1.65 EPS for the current year.

About Monopar Therapeutics

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.